# Xortx Therapeutics Inc. (XRTX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $2.18 (-4.39%)

> XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company dedicated to developing innovative therapies that target aberrant purine metabolism and xanthine oxidase to lower uric acid levels and treat gout and progressive kidney diseases. Its pipeline includes the lead XRx-026 program, advancing toward new drug application filing for gout treatment; XRx-008 in phase two for autosomal dominant polycystic kidney disease; XRx-101 in phase two for acute kidney injury and organ damage linked to respiratory virus infections; and preclinical XRx-225 for type 2 diabetic nephropathy. These programs address unmet needs in metabolic and renal disorders by modulating uric acid production. XORTX Therapeutics Inc. focuses on improving patient quality of life through first-in-class uric acid lowering agents for rare and chronic kidney conditions. Founded in 2009 and headquartered in Calgary, Alberta, the company advances these therapies through clinical development stages, emphasizing precision medicine approaches in the biopharmaceutical sector.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/XRTX)